Growth Hormone Secretagogue Approved overseas (e.g. United States) for HIV-associated lipodystrophy; not generally approved for general human use in Australia. Outside that indication, evidence is limited.

Tesamorelin

Also known as: Egrifta

Tesamorelin is a synthetic growth hormone releasing hormone (GHRH) analogue. It is approved overseas for HIV-associated lipodystrophy but is not generally approved for general human use in Australia.

Category: Growth Hormone Secretagogue
Reported half-life: Reported ~26-38 minutes (varies by study)
Common forms: Lyophilised powder for reconstitution, Injectable solution
Research status: Approved overseas (e.g. United States) for HIV-associated lipodystrophy; not generally approved for general human use in Australia. Outside that indication, evidence is limited.
Last updated: 21 June 2026

Claimed effects

The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.

Reported to stimulate the body's own release of growth hormone
Studied for reported reduction of visceral (abdominal) fat in HIV-associated lipodystrophy
Users report interest in body composition and recovery
Early research indicates possible effects on IGF-1 levels

How it is reported to work

Tesamorelin is reported to act as a stabilised analogue of growth hormone releasing hormone, binding GHRH receptors on the pituitary gland to prompt a more natural, pulsatile release of growth hormone. This is in turn proposed to raise IGF-1 and influence fat metabolism. These mechanisms are described in clinical literature for a specific HIV-related condition and should not be generalised.

Background

Tesamorelin is a synthetic growth hormone releasing hormone (GHRH) analogue. Unlike ghrelin-mimetics, it is reported to act higher up the pathway by signalling the pituitary to release the body’s own growth hormone. It is best known internationally for a single approved use: reducing excess visceral fat in people with HIV-associated lipodystrophy. This page is educational information, not medical advice.

What the research actually shows

Within its specific approved indication, tesamorelin has clinical trial data behind it. Outside that narrow context, claims about general body composition or anti-ageing benefits are not established and rely largely on extrapolation. Promising data in one condition does not transfer automatically to healthy individuals.

Evidence type	Status
Clinical trials (HIV lipodystrophy)	Present
General human use trials	Lacking
Australian general approval	None

What people use it for (reported)

Online, people report interest in tesamorelin for body composition and recovery. These are anecdotal reports outside the studied indication, not validated outcomes. Studies suggest effects on growth hormone and IGF-1, but reported benefits should not be read as established facts for general use.

Things to be aware of

Tesamorelin is not generally approved for general human use in Australia. Growth hormone pathway effects can influence blood glucose and fluid balance, and long-term consequences in healthy people are not well characterised. Grey-market product identity and purity cannot be verified by sight.

If you have a health concern, the appropriate step is to talk to a qualified healthcare professional rather than self-experimenting. This article is not an endorsement and does not recommend obtaining or using tesamorelin.

Reported positives & side effects

Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.

Reported positives

Reported to stimulate the body's own pulsatile growth-hormone release
Clinically studied to reduce visceral (abdominal) fat in HIV-associated lipodystrophy
Reported to raise IGF-1 levels
Users report interest in body composition and recovery
Reported to act higher up the pathway than ghrelin-mimetics, mimicking natural GHRH

Common side effects

Injection-site reactions such as redness, itching or pain
Joint pain or stiffness
Swelling or fluid retention in the limbs
Muscle aches
Tingling or numbness in the hands

Rare / serious side effects

Worsening of blood-sugar control or new glucose intolerance
Carpal-tunnel syndrome from sustained growth-hormone elevation
Allergic or hypersensitivity reactions
Reactions attributed to impurities in unregulated grey-market product

Reported misuse & overdose risks

What has been reported to happen with overuse, excessive dosing, or long-term misuse of Tesamorelin. Listed so you can make an informed decision, not to suggest any use is safe.

Use outside the narrow approved indication is reported to risk worsening blood sugar and glucose intolerance, a documented concern with sustained growth-hormone elevation
Prolonged overuse is reported to risk fluid retention, joint pain and carpal-tunnel symptoms consistent with growth-hormone excess
Sustained IGF-1 elevation from overuse raises a frequently cited theoretical concern about feeding abnormal tissue growth
Continuously stimulating the pituitary at high doses is reported to risk disrupting the natural pulsatile rhythm of growth-hormone release
Unverified grey-market product is reported to risk contamination and incorrect dosing

Reported results timeline

Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Changes are generally reported to build gradually, with measurable visceral-fat reduction reported over roughly three to six months in clinical use.

First effects
Subtle changes within the first week
Noticeable change
Body-composition shifts ~4-6 weeks
Clear results
Visceral-fat reduction reported by ~12 weeks
Peak effect
Fuller effects reported ~6 months

Commonly reported dosing & protocol

Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Tesamorelin. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.

Commonly reported dosing for Tesamorelin
Route	Subcutaneous injection
Typical reported dose	Reported figures of roughly 1–2 mg per dose
Frequency	Reported as once daily (commonly at night)
Cycle length	Reported cycles of about 8–12 weeks, then a break

Reported reconstitution (mg → units)

Worked example only: a 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL. A 1 mg dose ≈ 0.2 mL = 20 units on a U-100 insulin syringe; a 2 mg dose ≈ 0.4 mL = 40 units.

Work out the units for your vial → Calculator

In its studied indication it is reported to be used as an ongoing once-daily injection rather than a short cycle, with effects reported to reverse after stopping. Off-label community patterns describe daily dosing in cycles of several months. These are reported patterns only, not a recommendation, and tesamorelin is not generally approved for human use in Australia.

Best used with / commonly stacked with

Combinations people report using together. Reported, not recommended, stacking can increase risks.

Ipamorelin

Reported to be paired so a GHRH analogue and a ghrelin-mimetic together amplify the growth-hormone pulse

CJC-1295

Reported as an alternative or complementary GHRH-type peptide in growth-hormone stacks

Sermorelin

A related GHRH analogue that users compare or rotate with

Safety notes

Tesamorelin is not generally approved for general human use in Australia, and its overseas approval is narrow. Stimulating growth hormone pathways can carry risks such as effects on blood glucose and fluid balance, and grey-market purity cannot be verified by consumers. Anyone considering it should first consult a qualified healthcare professional.